« The Director Compensation Project: Sprint Nextel | Main | The Director Compensation Project: Morgan Stanley »
Tuesday
Apr292008

The Director Compensation Project: CVS Caremark

This post is part of an ongoing series that examines the way stock exchange independence rules influence director compensation. We are including companies from 2007’s Fortune 100 and using information disclosed in each company’s 2008 proxy statements. In addition to state standards and the requirements of SOX, the stock exchanges have each adopted their own standards for director independence. Meeting stock exchange requirements is mandatory for most listed companies.

Under NYSE Rule 303A.01, all listed companies must have a majority of independent directors sitting on their boards. Directors are not independent if they received over $100,000 in direct compensation, other than director’s fees, in any one year period over the last three years pursuant to Rule 303A.02(b)(ii). This is a looser restriction than the equivalent NASDAQ Rule, 4200(a)(15), which includes all compensation. Rule 303A.06 requires that, in addition to the general independence standards, audit committee members must comport with the requirements of Exchange Act Rule 10A-3 (C.F.R. §240.10A-3), also known as SOX 301.

One can see some of the effects of these rules when looking at the director compensation table from CVS Caremark’s (CVS-NYSE) 2008 proxy statement.

Name

Fees Earned
and Paid
in Cash
($)

Cash Fees
Elected to be
Paid in Stock (1)
($)

Stock
Awards (1)
($)

All Other
Compen-

 sation (2)
($)

Total
($)

Edwin M. Banks (3)

45,500

286,448

10,894

342,842

C. David Brown II (3)

1,000

45,278

286,448

2,624

335,350

Edwin M. Crawford (3) (4)

10,833

100,370

57,795

168,998

David W. Dorman

70,833

184,580

255,413

Thomas P. Gerrity (5)

10,000

126,607

136,607

Kristen Gibney Williams (3)

48,500

286,448

875

335,823

Roger L. Headrick (3) (6)

1,000

34,191

294,544

1,838

331,573

Marian L. Heard

68,500

184,580

253,080

William H. Joyce

63,500

184,580

248,080

Jean-Pierre Millon (3)

1,000

44,278

286,448

331,726

Terrence Murray

24,000

32,474

184,554

241,028

C. A. Lance Piccolo (3)

10,000

32,474

286,448

6,141

335,063

Sheli Z. Rosenberg

70,035

184,554

254,589

Richard J. Swift

59,500

133,785

193,285

Alfred J. Verrecchia (5)

9,000

126,607

135,607

Director Compensation : CVS Caremark’s board met twelve times last year. Each director attended at least 75% of the meetings, except Mr. Edwin M. Banks, who attended slightly fewer meetings . The non-employee directors as a group averaged $259,938 in total compensation for their services. As can be seen in the table, much of the directors’ compensation came in the form of stock awards and cash fees elected to be paid in stock.

Director Tenure : On average, the non-employee directors have served on the board for five years. William H. Joyce has the longest tenure at thirteen years. All but one of the directors also sits on other boards. One director alone sits on four additional boards: Avis Budget Group, Equity Lifestyle Properties, Ventas, and Nanosphere.

CEO Compensation : The CEO, Thomas M. Ryan, received $ 26,097,790 in total compensation last year, a relatively small portion of which came in the form of cash ($1,350,000). A portion of his compensation ($556,732) was in the form of “other compensation.” This included $118,468 for personal aircraft usage. Mr. Ryan received $9,390,798 in the form of stock awards, and $3,486,931 in the form of option awards, which were dependant upon company performance.

Reader Comments

There are no comments for this journal entry. To create a new comment, use the form below.

PostPost a New Comment

Enter your information below to add a new comment.

My response is on my own website »
Author Email (optional):
Author URL (optional):
Post:
 
All HTML will be escaped. Hyperlinks will be created for URLs automatically.